img

Global Dry Age-Related Macular Degeneration Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Dry Age-Related Macular Degeneration Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Dry macular degeneration is a common eye disorder among people over 50. It causes blurred or reduced central vision, due to thinning of the macula (MAK-u-luh). The macula is the part of the retina responsible for clear vision in your direct line of sight.
Due to the COVID-19 pandemic, the global Dry Age-Related Macular Degeneration market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Oral accounting for % of the Dry Age-Related Macular Degeneration global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Above 40 Years segment is altered to an % CAGR throughout this forecast period.
The global key companies of Dry Age-Related Macular Degeneration include Santen Pharmaceuticals, Allergan, Bausch Health, Alimera Science, Phio Pharmaceuticals, Ocumension Therapeutics, Belite Bio, Kubota Vision and Iveric Bio, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Dry Age-Related Macular Degeneration market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Dry Age-Related Macular Degeneration landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Dry Age-Related Macular Degeneration market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Dry Age-Related Macular Degeneration market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Dry Age-Related Macular Degeneration market. Readers of the report can become informed about current and future trends of the global Dry Age-Related Macular Degeneration market and how they will impact market growth during the forecast period.



By Company


Santen Pharmaceuticals
Allergan
Bausch Health
Alimera Science
Phio Pharmaceuticals
Ocumension Therapeutics
Belite Bio
Kubota Vision
Iveric Bio
Eyestem Research
Y2 Solution
Stealth Biotherapeutics
Segment by Type
Oral
Injectables

Segment by Application


Above 40 Years
Above 60 Years
Above 75 Years
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Dry Age-Related Macular Degeneration in global and regional level.
Chapter 3Detailed analysis of Dry Age-Related Macular Degeneration companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dry Age-Related Macular Degeneration revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dry Age-Related Macular Degeneration Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Oral
1.2.3 Injectables
1.3 Market by Application
1.3.1 Global Dry Age-Related Macular Degeneration Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Above 40 Years
1.3.3 Above 60 Years
1.3.4 Above 75 Years
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Dry Age-Related Macular Degeneration Market Size (2018-2034)
2.2 Dry Age-Related Macular Degeneration Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Dry Age-Related Macular Degeneration Market Size by Region (2018-2024)
2.4 Global Dry Age-Related Macular Degeneration Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Dry Age-Related Macular Degeneration Countries Ranking by Market Size
3 Dry Age-Related Macular Degeneration Competitive by Company
3.1 Global Dry Age-Related Macular Degeneration Revenue by Players
3.1.1 Global Dry Age-Related Macular Degeneration Revenue by Players (2018-2024)
3.1.2 Global Dry Age-Related Macular Degeneration Market Share by Players (2018-2024)
3.2 Global Dry Age-Related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Dry Age-Related Macular Degeneration Revenue
3.4 Global Dry Age-Related Macular Degeneration Market Concentration Ratio
3.4.1 Global Dry Age-Related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dry Age-Related Macular Degeneration Revenue in 2022
3.5 Global Key Players of Dry Age-Related Macular Degeneration Head office and Area Served
3.6 Global Key Players of Dry Age-Related Macular Degeneration, Product and Application
3.7 Global Key Players of Dry Age-Related Macular Degeneration, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Dry Age-Related Macular Degeneration Breakdown Data by Type
4.1 Global Dry Age-Related Macular Degeneration Historic Revenue by Type (2018-2024)
4.2 Global Dry Age-Related Macular Degeneration Forecasted Revenue by Type (2024-2034)
5 Global Dry Age-Related Macular Degeneration Breakdown Data by Application
5.1 Global Dry Age-Related Macular Degeneration Historic Market Size by Application (2018-2024)
5.2 Global Dry Age-Related Macular Degeneration Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Dry Age-Related Macular Degeneration Revenue by Company (2021-2024)
6.2 North America Dry Age-Related Macular Degeneration Revenue by Type (2018-2034)
6.3 North America Dry Age-Related Macular Degeneration Revenue by Application (2018-2034)
6.4 North America Dry Age-Related Macular Degeneration Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Dry Age-Related Macular Degeneration Revenue by Company (2021-2024)
7.2 Europe Dry Age-Related Macular Degeneration Revenue by Type (2018-2034)
7.3 Europe Dry Age-Related Macular Degeneration Revenue by Application (2018-2034)
7.4 Europe Dry Age-Related Macular Degeneration Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Dry Age-Related Macular Degeneration Revenue by Company (2021-2024)
8.2 Asia Pacific Dry Age-Related Macular Degeneration Revenue by Type (2018-2034)
8.3 Asia Pacific Dry Age-Related Macular Degeneration Revenue by Application (2018-2034)
8.4 Asia Pacific Dry Age-Related Macular Degeneration Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Dry Age-Related Macular Degeneration Revenue by Company (2021-2024)
9.2 Latin America Dry Age-Related Macular Degeneration Revenue by Type (2018-2034)
9.3 Latin America Dry Age-Related Macular Degeneration Revenue by Application (2018-2034)
9.4 Latin America Dry Age-Related Macular Degeneration Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Company (2021-2024)
10.2 Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Type (2018-2034)
10.3 Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Application (2018-2034)
10.4 Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Santen Pharmaceuticals
11.1.1 Santen Pharmaceuticals Company Details
11.1.2 Santen Pharmaceuticals Business Overview
11.1.3 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Products and Services
11.1.4 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.1.5 Santen Pharmaceuticals Dry Age-Related Macular Degeneration SWOT Analysis
11.1.6 Santen Pharmaceuticals Recent Development
11.2 Allergan
11.2.1 Allergan Company Details
11.2.2 Allergan Business Overview
11.2.3 Allergan Dry Age-Related Macular Degeneration Products and Services
11.2.4 Allergan Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.2.5 Allergan Dry Age-Related Macular Degeneration SWOT Analysis
11.2.6 Allergan Recent Development
11.3 Bausch Health
11.3.1 Bausch Health Company Details
11.3.2 Bausch Health Business Overview
11.3.3 Bausch Health Dry Age-Related Macular Degeneration Products and Services
11.3.4 Bausch Health Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.3.5 Bausch Health Dry Age-Related Macular Degeneration SWOT Analysis
11.3.6 Bausch Health Recent Development
11.4 Alimera Science
11.4.1 Alimera Science Company Details
11.4.2 Alimera Science Business Overview
11.4.3 Alimera Science Dry Age-Related Macular Degeneration Products and Services
11.4.4 Alimera Science Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.4.5 Alimera Science Dry Age-Related Macular Degeneration SWOT Analysis
11.4.6 Alimera Science Recent Development
11.5 Phio Pharmaceuticals
11.5.1 Phio Pharmaceuticals Company Details
11.5.2 Phio Pharmaceuticals Business Overview
11.5.3 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Products and Services
11.5.4 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.5.5 Phio Pharmaceuticals Dry Age-Related Macular Degeneration SWOT Analysis
11.5.6 Phio Pharmaceuticals Recent Development
11.6 Ocumension Therapeutics
11.6.1 Ocumension Therapeutics Company Details
11.6.2 Ocumension Therapeutics Business Overview
11.6.3 Ocumension Therapeutics Dry Age-Related Macular Degeneration Products and Services
11.6.4 Ocumension Therapeutics Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.6.5 Ocumension Therapeutics Dry Age-Related Macular Degeneration SWOT Analysis
11.6.6 Ocumension Therapeutics Recent Development
11.7 Belite Bio
11.7.1 Belite Bio Company Details
11.7.2 Belite Bio Business Overview
11.7.3 Belite Bio Dry Age-Related Macular Degeneration Products and Services
11.7.4 Belite Bio Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.7.5 Belite Bio Dry Age-Related Macular Degeneration SWOT Analysis
11.7.6 Belite Bio Recent Development
11.8 Kubota Vision
11.8.1 Kubota Vision Company Details
11.8.2 Kubota Vision Business Overview
11.8.3 Kubota Vision Dry Age-Related Macular Degeneration Products and Services
11.8.4 Kubota Vision Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.8.5 Kubota Vision Dry Age-Related Macular Degeneration SWOT Analysis
11.8.6 Kubota Vision Recent Development
11.9 Iveric Bio
11.9.1 Iveric Bio Company Details
11.9.2 Iveric Bio Business Overview
11.9.3 Iveric Bio Dry Age-Related Macular Degeneration Products and Services
11.9.4 Iveric Bio Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.9.5 Iveric Bio Dry Age-Related Macular Degeneration SWOT Analysis
11.9.6 Iveric Bio Recent Development
11.10 Eyestem Research
11.10.1 Eyestem Research Company Details
11.10.2 Eyestem Research Business Overview
11.10.3 Eyestem Research Dry Age-Related Macular Degeneration Products and Services
11.10.4 Eyestem Research Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.10.5 Eyestem Research Dry Age-Related Macular Degeneration SWOT Analysis
11.10.6 Eyestem Research Recent Development
11.11 Y2 Solution
11.11.1 Y2 Solution Company Details
11.11.2 Y2 Solution Business Overview
11.11.3 Y2 Solution Dry Age-Related Macular Degeneration Products and Services
11.11.4 Y2 Solution Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.11.5 Y2 Solution Recent Development
11.12 Stealth Biotherapeutics
11.12.1 Stealth Biotherapeutics Company Details
11.12.2 Stealth Biotherapeutics Business Overview
11.12.3 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Products and Services
11.12.4 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.12.5 Stealth Biotherapeutics Recent Development
12 Dry Age-Related Macular Degeneration Market Dynamics
12.1 Dry Age-Related Macular Degeneration Industry Trends
12.2 Dry Age-Related Macular Degeneration Market Drivers
12.3 Dry Age-Related Macular Degeneration Market Challenges
12.4 Dry Age-Related Macular Degeneration Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Dry Age-Related Macular Degeneration Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Oral
Table 3. Key Players of Injectables
Table 4. Global Dry Age-Related Macular Degeneration Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 5. Global Dry Age-Related Macular Degeneration Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 6. Global Dry Age-Related Macular Degeneration Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Dry Age-Related Macular Degeneration Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 8. Global Dry Age-Related Macular Degeneration Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 9. Global Dry Age-Related Macular Degeneration Revenue by Players (2018-2024) & (US$ Million)
Table 10. Global Dry Age-Related Macular Degeneration Market Share by Players (2018-2024)
Table 11. Global Top Dry Age-Related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dry Age-Related Macular Degeneration as of 2022)
Table 12. Ranking of Global Top Dry Age-Related Macular Degeneration Companies by Revenue (US$ Million) in 2022
Table 13. Global 5 Largest Players Market Share by Dry Age-Related Macular Degeneration Revenue (CR5 and HHI) & (2018-2024)
Table 14. Global Key Players of Dry Age-Related Macular Degeneration, Headquarters and Area Served
Table 15. Global Key Players of Dry Age-Related Macular Degeneration, Product and Application
Table 16. Global Key Players of Dry Age-Related Macular Degeneration, Date of Enter into This Industry
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Global Dry Age-Related Macular Degeneration Market Size by Type (2018-2024) & (US$ Million)
Table 19. Global Dry Age-Related Macular Degeneration Revenue Market Share by Type (2018-2024)
Table 20. Global Dry Age-Related Macular Degeneration Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 21. Global Dry Age-Related Macular Degeneration Revenue Market Share by Type (2024-2034)
Table 22. Global Dry Age-Related Macular Degeneration Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Dry Age-Related Macular Degeneration Revenue Market Share by Application (2018-2024)
Table 24. Global Dry Age-Related Macular Degeneration Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Dry Age-Related Macular Degeneration Revenue Market Share by Application (2024-2034)
Table 26. North America Dry Age-Related Macular Degeneration Revenue by Company (2021-2024) & (US$ Million)
Table 27. North America Dry Age-Related Macular Degeneration Revenue by Type (2018-2024) & (US$ Million)
Table 28. North America Dry Age-Related Macular Degeneration Revenue by Type (2024-2034) & (US$ Million)
Table 29. North America Dry Age-Related Macular Degeneration Revenue by Application (2018-2024) & (US$ Million)
Table 30. North America Dry Age-Related Macular Degeneration Revenue by Application (2024-2034) & (US$ Million)
Table 31. North America Dry Age-Related Macular Degeneration Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 32. North America Dry Age-Related Macular Degeneration Revenue by Country (2018-2024) & (US$ Million)
Table 33. North America Dry Age-Related Macular Degeneration Revenue by Country (2024-2034) & (US$ Million)
Table 34. Europe Dry Age-Related Macular Degeneration Revenue by Company (2021-2024) & (US$ Million)
Table 35. Europe Dry Age-Related Macular Degeneration Revenue by Type (2018-2024) & (US$ Million)
Table 36. Europe Dry Age-Related Macular Degeneration Revenue by Type (2024-2034) & (US$ Million)
Table 37. Europe Dry Age-Related Macular Degeneration Revenue by Application (2018-2024) & (US$ Million)
Table 38. Europe Dry Age-Related Macular Degeneration Revenue by Application (2024-2034) & (US$ Million)
Table 39. Europe Dry Age-Related Macular Degeneration Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 40. Europe Dry Age-Related Macular Degeneration Revenue by Country (2018-2024) & (US$ Million)
Table 41. Europe Dry Age-Related Macular Degeneration Revenue by Country (2024-2034) & (US$ Million)
Table 42. Asia Pacific Dry Age-Related Macular Degeneration Revenue by Company (2021-2024) & (US$ Million)
Table 43. Asia Pacific Dry Age-Related Macular Degeneration Revenue by Type (2018-2024) & (US$ Million)
Table 44. Asia Pacific Dry Age-Related Macular Degeneration Revenue by Type (2024-2034) & (US$ Million)
Table 45. Asia Pacific Dry Age-Related Macular Degeneration Revenue by Application (2018-2024) & (US$ Million)
Table 46. Asia Pacific Dry Age-Related Macular Degeneration Revenue by Application (2024-2034) & (US$ Million)
Table 47. Asia-Pacific Dry Age-Related Macular Degeneration Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 48. Asia Pacific Dry Age-Related Macular Degeneration Revenue by Region (2018-2024) & (US$ Million)
Table 49. Asia Pacific Dry Age-Related Macular Degeneration Revenue by Region (2024-2034) & (US$ Million)
Table 50. Latin America Dry Age-Related Macular Degeneration Revenue by Company (2021-2024) & (US$ Million)
Table 51. Latin America Dry Age-Related Macular Degeneration Revenue by Type (2018-2024) & (US$ Million)
Table 52. Latin America Dry Age-Related Macular Degeneration Revenue by Type (2024-2034) & (US$ Million)
Table 53. Latin America Dry Age-Related Macular Degeneration Revenue by Application (2018-2024) & (US$ Million)
Table 54. Latin America Dry Age-Related Macular Degeneration Revenue by Application (2024-2034) & (US$ Million)
Table 55. Latin America Dry Age-Related Macular Degeneration Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 56. Latin America Dry Age-Related Macular Degeneration Revenue by Country (2018-2024) & (US$ Million)
Table 57. Latin America Dry Age-Related Macular Degeneration Revenue by Country (2024-2034) & (US$ Million)
Table 58. Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Company (2021-2024) & (US$ Million)
Table 59. Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Type (2018-2024) & (US$ Million)
Table 60. Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Type (2024-2034) & (US$ Million)
Table 61. Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Application (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Application (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Dry Age-Related Macular Degeneration Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 64. Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Country (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Dry Age-Related Macular Degeneration Revenue by Country (2024-2034) & (US$ Million)
Table 66. Santen Pharmaceuticals Company Details
Table 67. Santen Pharmaceuticals Business Overview
Table 68. Santen Pharmaceuticals Dry Age-Related Macular Degeneration Product and Services
Table 69. Santen Pharmaceuticals Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 70. Santen Pharmaceuticals Dry Age-Related Macular Degeneration SWOT Analysis
Table 71. Santen Pharmaceuticals Recent Development
Table 72. Allergan Company Details
Table 73. Allergan Business Overview
Table 74. Allergan Dry Age-Related Macular Degeneration Product and Services
Table 75. Allergan Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 76. Allergan Dry Age-Related Macular Degeneration SWOT Analysis
Table 77. Allergan Recent Development
Table 78. Bausch Health Company Details
Table 79. Bausch Health Business Overview
Table 80. Bausch Health Dry Age-Related Macular Degeneration Product and Services
Table 81. Bausch Health Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 82. Bausch Health Dry Age-Related Macular Degeneration SWOT Analysis
Table 83. Bausch Health Recent Development
Table 84. Alimera Science Company Details
Table 85. Alimera Science Business Overview
Table 86. Alimera Science Dry Age-Related Macular Degeneration Product and Services
Table 87. Alimera Science Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 88. Alimera Science Dry Age-Related Macular Degeneration SWOT Analysis
Table 89. Alimera Science Recent Development
Table 90. Phio Pharmaceuticals Company Details
Table 91. Phio Pharmaceuticals Business Overview
Table 92. Phio Pharmaceuticals Dry Age-Related Macular Degeneration Product and Services
Table 93. Phio Pharmaceuticals Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 94. Phio Pharmaceuticals Dry Age-Related Macular Degeneration SWOT Analysis
Table 95. Phio Pharmaceuticals Recent Development
Table 96. Ocumension Therapeutics Company Details
Table 97. Ocumension Therapeutics Business Overview
Table 98. Ocumension Therapeutics Dry Age-Related Macular Degeneration Product and Services
Table 99. Ocumension Therapeutics Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 100. Ocumension Therapeutics Dry Age-Related Macular Degeneration SWOT Analysis
Table 101. Ocumension Therapeutics Recent Development
Table 102. Belite Bio Company Details
Table 103. Belite Bio Business Overview
Table 104. Belite Bio Dry Age-Related Macular Degeneration Product and Services
Table 105. Belite Bio Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 106. Belite Bio Dry Age-Related Macular Degeneration SWOT Analysis
Table 107. Belite Bio Recent Development
Table 108. Kubota Vision Company Details
Table 109. Kubota Vision Business Overview
Table 110. Kubota Vision Dry Age-Related Macular Degeneration Product and Services
Table 111. Kubota Vision Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 112. Kubota Vision Dry Age-Related Macular Degeneration SWOT Analysis
Table 113. Kubota Vision Recent Development
Table 114. Iveric Bio Company Details
Table 115. Iveric Bio Business Overview
Table 116. Iveric Bio Dry Age-Related Macular Degeneration Product and Services
Table 117. Iveric Bio Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 118. Iveric Bio Dry Age-Related Macular Degeneration SWOT Analysis
Table 119. Iveric Bio Recent Development
Table 120. Eyestem Research Company Details
Table 121. Eyestem Research Business Overview
Table 122. Eyestem Research Dry Age-Related Macular Degeneration Product and Services
Table 123. Eyestem Research Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 124. Eyestem Research Dry Age-Related Macular Degeneration SWOT Analysis
Table 125. Eyestem Research Recent Development
Table 126. Y2 Solution Company Details
Table 127. Y2 Solution Business Overview
Table 128. Y2 Solution Dry Age-Related Macular Degeneration Product and Services
Table 129. Y2 Solution Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 130. Y2 Solution Recent Development
Table 131. Stealth Biotherapeutics Company Details
Table 132. Stealth Biotherapeutics Business Overview
Table 133. Stealth Biotherapeutics Dry Age-Related Macular Degeneration Product and Services
Table 134. Stealth Biotherapeutics Dry Age-Related Macular Degeneration Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 135. Stealth Biotherapeutics Recent Development
Table 136. Dry Age-Related Macular Degeneration Market Trends
Table 137. Dry Age-Related Macular Degeneration Market Drivers
Table 138. Dry Age-Related Macular Degeneration Market Challenges
Table 139. Dry Age-Related Macular Degeneration Market Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Dry Age-Related Macular Degeneration Product Picture
Figure 2. Global Dry Age-Related Macular Degeneration Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Dry Age-Related Macular Degeneration Market Share by Type: 2022 VS 2034
Figure 4. Oral Features
Figure 5. Injectables Features
Figure 6. Global Dry Age-Related Macular Degeneration Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 7. Global Dry Age-Related Macular Degeneration Market Share by Application: 2022 VS 2034
Figure 8. Above 40 Years
Figure 9. Above 60 Years
Figure 10. Above 75 Years
Figure 11. Dry Age-Related Macular Degeneration Report Years Considered
Figure 12. Global Dry Age-Related Macular Degeneration Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Dry Age-Related Macular Degeneration Market Size 2018-2034 (US$ Million)
Figure 14. Global Dry Age-Related Macular Degeneration Market Size Market Share by Region: 2022 VS 2034
Figure 15. Global Dry Age-Related Macular Degeneration Revenue Market Share by Region in 2018 VS 2022
Figure 16. Global Dry Age-Related Macular Degeneration Revenue Market Share Forecast by Region (2024-2034)
Figure 17. Global Top 10 Dry Age-Related Macular Degeneration Countries Ranking by Market Size (US$ Million) in 2022
Figure 18. Global Dry Age-Related Macular Degeneration Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 19. Global Dry Age-Related Macular Degeneration Market Share by Players in 2022
Figure 20. Global Top Dry Age-Related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dry Age-Related Macular Degeneration as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Dry Age-Related Macular Degeneration Revenue in 2022
Figure 22. North America Dry Age-Related Macular Degeneration Revenue Market Share by Company in 2022
Figure 23. North America Dry Age-Related Macular Degeneration Revenue Market Share by Type (2018-2034)
Figure 24. North America Dry Age-Related Macular Degeneration Revenue Market Share by Application (2018-2034)
Figure 25. North America Dry Age-Related Macular Degeneration Revenue Share by Country (2018-2034)
Figure 26. United States Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 27. Canada Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 28. Europe Dry Age-Related Macular Degeneration Revenue Market Share by Company in 2022
Figure 29. Europe Dry Age-Related Macular Degeneration Revenue Market Share by Type (2018-2034)
Figure 30. Europe Dry Age-Related Macular Degeneration Revenue Market Share by Application (2018-2034)
Figure 31. Europe Dry Age-Related Macular Degeneration Revenue Share by Country (2018-2034)
Figure 32. Germany Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 33. France Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 34. U.K. Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 35. Italy Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 36. Russia Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 37. Asia Pacific Dry Age-Related Macular Degeneration Revenue Market Share by Company in 2022
Figure 38. Asia Pacific Dry Age-Related Macular Degeneration Revenue Market Share by Type (2018-2034)
Figure 39. Asia Pacific Dry Age-Related Macular Degeneration Revenue Market Share by Application (2018-2034)
Figure 40. Asia Pacific Dry Age-Related Macular Degeneration Revenue Share by Region (2018-2034)
Figure 41. China Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 42. Japan Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 43. South Korea Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 44. India Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 45. Australia Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 46. China Taiwan Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 47. Indonesia Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 48. Thailand Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 49. Malaysia Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 50. Latin America Dry Age-Related Macular Degeneration Revenue Market Share by Company in 2022
Figure 51. Latin America Dry Age-Related Macular Degeneration Revenue Market Share by Type (2018-2034)
Figure 52. Latin America Dry Age-Related Macular Degeneration Revenue Market Share by Application (2018-2034)
Figure 53. Latin America Dry Age-Related Macular Degeneration Revenue Share by Country (2018-2034)
Figure 54. Mexico Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 55. Brazil Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 56. Argentina Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 57. Middle East and Africa Dry Age-Related Macular Degeneration Revenue Market Share by Company in 2022
Figure 58. Middle East and Africa Dry Age-Related Macular Degeneration Revenue Market Share by Type (2018-2034)
Figure 59. Middle East and Africa Dry Age-Related Macular Degeneration Revenue Market Share by Application (2018-2034)
Figure 60. Middle East and Africa Dry Age-Related Macular Degeneration Revenue Share by Country (2018-2034)
Figure 61. Turkey Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 62. Saudi Arabia Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 63. UAE Dry Age-Related Macular Degeneration Revenue (2018-2034) & (US$ Million)
Figure 64. Santen Pharmaceuticals Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 65. Allergan Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 66. Bausch Health Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 67. Alimera Science Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 68. Phio Pharmaceuticals Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 69. Ocumension Therapeutics Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 70. Belite Bio Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 71. Kubota Vision Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 72. Iveric Bio Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 73. Eyestem Research Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 74. Y2 Solution Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 75. Stealth Biotherapeutics Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed